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Background:  In patients with hypertrophic cardiomyopathy (HCM), cardiovascular magnetic resonance (CMR) can detect morphologic 
abnormalities of the left ventricular (LV) myocardium not appreciated with 2-dimensional echocardiography. Myocardial crypts (ie., narrow, blood-
filled distinctive invaginations within the LV wall) have been reported but the clinical significance and diagnostic power of this novel CMR finding 
remains incompletely resolved.
Methods:  Cine and late gadolinium enhancement (LGE) CMR and 2-dimensional echocardiography were obtained in consecutive patients: 
23 genotype positive/phenotype negative HCM family members without LV hypertrophy (27±17 years; 61% male); 268 HCM patients with LV 
hypertrophy (50±15 years; 70% male); and 98 healthy adult subjects without cardiovascular disease. CMR images were evaluated for myocardial 
crypts and compared to relevant clinical and imaging variables.
Results:  Myocardial crypts, 1-5 per patient, were identified only by CMR in 14 of the 23 (61%) genotype positive/phenotype negative HCM 
patients, in 10 of 268 (4%) HCM patients and in none of 98 controls (p<0.001). In both patient groups, crypts were confined to the basal or 
mid-level of the LV and most commonly located in the ventricular septum (n=14, 58%) and inferior wall (n=8, 33%), associated with normal LV 
segmental contractility and absence of late gadolinium enhancement. 12-lead ECGs were normal in 7 (50%) of the genotype positive/phenotype 
negative patients with crypts.
Conclusions:  Myocardial crypts that are identified only by CMR are part of the phenotypic expression of HCM, but are found predominantly in 
the subgroup of genotype positive/phenotype negative patients. LV myocardial crypts may represent the only morphologic manifestation of HCM in 
affected family members in the absence of LV hypertrophy, and a novel marker for whom CMR is the sole means of clinical diagnosis. These data 
support a potential expanded role for CMR in the earlier evaluation of HCM family members.
